Objective:To explore the effect of long noncoding RNA ANK3DT (lncRNA ANK3DT) on DNA damage repair ability and radiosensitivity of cervical cancer HeLa cells.Methods:The effect of lncRNA ANK3DT on the repair efficiency of DNA double-strand breaks (DSBs) was analyzed by the pre-constructed quantitative assay system based on the CRISPR/Cas9 system targeting homologous recombination (HR) and non-homologous end-joining (NHEJ) repair. Clone formation assay, flow cytometry, and immunofluorescence were used to detect the effects of down-regulation of lncRNA ANK3DT on cellular radiosensitivity, apoptosis and G 2/M phase arrest, and DSB repair after X-ray irradiation. Western blot, qPCR, and dual fluorokinase reporter gene plasmid was used to detect the effects of lncRNA ANK3DT on the HR repair-related protein CtIP expression and transcriptional regulation. Results:Down-regulation of lncRNA ANK3DT significantly inhibited HR repair and had no effect on NHEJ repair. The expression of lncRNA ANK3DT was significantly increased in HeLa cells at 24, 48, 72 h after X-ray irradiation ( t=-23.39, -88.83, -52.42, P<0.05). Down-regulation of lncRNA ANK3DT inhibited X-ray-induced DSB repair and increased apoptosis levels ( t=-14.63, P <0.05), prolonged G 2/M phase block ( t=-19.50, P <0.05), increased the radiosensitivity of HeLa cells (radiosensitization ratio=1.21), inhibited the CtIP promoter activity and decreased its mRNA and protein expression. Conclusions:lncRNA ANK3DT affects HR repair by regulating CtIP transcription, and down-regulation of lncRNA ANK3DT increases the radiosensitivity of HeLa cells by inhibiting DSB repair after ionizing radiation.

OBJECTIVE To investigate the changes of etiological submission rates before the antimicrobial therapy after a series of intervention measures were taken so as to optimize the use and management of antibiotics.METHODS A total of 97,146 patients who were hospitalized and treated with antibiotics in the First Affiliated Hospital of Soochow University from Jul.2021 to Jun.2024 were recruited as the research subjects.Jan.2023 was set as the time node of intervention,the time period from Jul.2021 to Dec.2022 was assigned as the pre-interven-tion group,and the time period from Jan.2023 to Jun.2024 was assigned as the post-intervention group.The etio-logical submission rates before the antimicrobial therapy were observed by interrupted time series before and after the intervention measures were taken.The changes of isolation rates of multidrug-resistant organisms and inci-dence of hospital-associated infections were estimated by chi-square test.RESULTS The etiological submission rates before the antimicrobial therapy,etiological submission rates before combined use of major antibiotics and etiological submission rates relating to diagnosis of hospital-associated infections were higher after the intervention than before the intervention(all P＜0.05).The interrupted time series analysis showed that from the perspective of long-term benefit,the intervention measures could raise the etiological submission rates before the use of re-stricted,special grades of antibiotics and general antibiotics,and the net benefits were 0.85％,0.67％and 0.68％,respectively(all P＜0.05);there was no significant difference in the etiological submission rate before the com-bined use of major antibiotics.After the intervention,the incidence of multidrug-resistant organisms infection de-creased from 0.46％to 0.27％(P＜0.001);the isolation rate of multidrug-resistant organisms was 25.73％after the intervention,27.47％before the intervention,and there was no significant difference.CONCLUSIONS Scientif-ic and reasonable interventions may effectively raise the etiological submission rates before the antimicrobial thera-py,however,the etiological submission rate for combined use of major antibiotics and the isolation rate of multi-drug-resistant organisms are not improved remarkably.It is necessary to further formulate targeted interven-tion measures so as to push forward high-quality development of infection control.

Objective:To develop a novel fibroblast activation protein (FAP) cyclic peptide imaging agent, Al 18F-FAP-NOX, evaluate its in vitro and in vivo properties, and explore its feasibility of PET/CT imaging in tumors with FAP positive expression. Methods:Al 18F-FAP-NOX was manually synthesized. The in vitro stability of Al 18F-FAP-NOX was determined using radio high performance liquid chromatography (HPLC). The lipid water partition coefficient log P, in vitro cell uptake experiments, microPET/CT imaging and biodistribution in 293T-FAP tumor-bearing mice were conducted to preliminarily evaluate the pharmacokinetics and biological efficacy of Al 18F-FAP-NOX. Afterwards, a patient (male, 65 years old) with lung cancer underwent Al 18F-FAP-NOX PET/CT imaging. Results:Al 18F-FAP-NOX was successfully synthesized with a yield of (26.28±2.31)% without attenuation correction ( n=4), and the radiochemical purity was more than 95%. Al 18F-FAP-NOX exhibited good stability and hydrophilicity (log P=-3.02±0.08, n=5). In cell assays, the uptake of Al 18F-FAP-NOX in HT1080-FAP cells reached the plateau phase at 15 min ((7.31±0.53) percentage activity of injection dose per million cells (%ID/mio cells)), exhibiting high cellular uptake. The uptake of Al 18F-FAP-NOX could be significantly inhibited by 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)-FAP-2286. The microPET/CT results of 293T-FAP tumor-bearing mice in vivo showed that Al 18F-FAP-NOX was highly uptaken in FAP-positive tumor tissues (60 min: (12.47±1.66) percentage activity of injection dose per gram of tissue (%ID/g)), while the uptake was very low in FAP-negative tumors. The biodistribution results were similar to the microPET/CT imaging results of tumor-bearing mice. The human clinical imaging showed an abnormal increase in Al 18F-FAP-NOX uptake (SUV max 5.5) of the lung cancer lesions. Conclusions:A novel cyclic peptide radiopharmaceutical, Al 18F-FAP-NOX, demonstrates good stability and hydrophilicity. It can be quickly distributed to tumor tissue in vivo. The human clinical PET/CT imaging shows certain diagnostic ability of Al 18F-FAP-NOX for lung cancer lesions. It is a promising cyclic peptide agent for PET imaging.

Objective:To systematically evaluate the safety and efficacy of the novel fibroblast activation protein (FAP)-targeted tracer 64Cu-FAP inhibitor (FAPI)-XT117 in patients with malignant solid tumors, and to compare with 18F-FDG. Methods:This self-controlled study was conducted on fifteen patients (8 males, 7 females; age (60 ±9) years) with malignant solid tumors from the First Affiliated Hospital of Guangzhou Medical University between July 2023 and December 2023. Each subject underwent 64Cu-FAPI-XT117 PET/CT at 30, 60, and 120min post-injection and was assigned to three dose cohorts (111MBq, 148MBq, and 185MBq; 5 patients in each cohort), and safety assessments were conducted within 24h after injection. In addition, all patients underwent 18F-FDG PET/CT at 60min post-injection. Time-activity curves were generated for 64Cu-FAPI-XT117, and the dosimetry was calculated. Image quality was evaluated using a 5-point Likert scale, and the optimal injected activity and imaging time point were determined. The paired t test was used to compare differences of the lesion detection count and SUV max between 64Cu-FAPI-XT117 and 18F-FDG PET/CT. Results:64Cu-FAPI-XT117 was well tolerated, with no adverse events reported. Time-activity curves of 68Ga-FAPI-XT117 revealed prominent uptake in the uterus, while the background activity in other organs remained low, with the whole-body effective dose of (0.0084±0.0021)mSv/MBq. The optimal imaging time point for 64Cu-FAPI-XT117 PET/CT was 60min post-injection, with an optimal administered activity of 111MBq. Compared with 18F-FDG, 64Cu-FAPI-XT117 demonstrated significantly higher uptake and more lesions in lymph-node metastases (SUV max: 8.6±3.8 vs 15.3±6.8, t=2.33, P=0.048; number of lesions: 8.3±5.4 vs 15.0±6.4; t=4.21, P=0.003) and distant metastases (SUV max: 11.8±3.7 vs 20.9±7.2, t=3.66, P=0.022; number of lesions: 7.0±3.2 vs 12.4±3.7, t=2.86, P=0.046). Conclusions:64Cu-FAPI-XT117 PET/CT is well tolerated in patients with solid tumors, with a controllable radiation risk. Moreover, it outperforms 18F-FDG PET/CT in the assessment of metastases.

AIM: To investigate the mechanism of Hexue Mingmu Tablets(HXMMT)in improving diabetic retinopathy(DR)based on transcriptomics.METHODS: Zebrafish DR models were established by 3-day glucose induction(130 mmol/L)starting at 3 days post-fertilization(dpf). Larvae were randomized into four groups: control group(CG; aquaculture water), model group(MG; 130 mmol/L glucose), low-dose HXMMT treatment group(L-HX; 130 mmol/L glucose +7.5 mg/L HXMMT), and high-dose HXMMT treatment group(H-HX; 130 mmol/L glucose +75 mg/L HXMMT), with a 3-day intervention period until 6 dpf. The area and length of eyes, and body length of zebrafish were observed by stereomicroscopy, retinal morphology was observed by hematoxylin-eosin staining(HE), and retinal vessel diameter was observed under fluorescence microscope. Differentially expressed genes(DEGs)were identified by RNA-sequencing(RNA-seq)technology to further elucidate the molecular mechanism of HXMMT in improving DR in zebrafish, and the sequencing accuracy was validated through quantitative real-time polymerase chain reaction(qRT-PCR).RESULTS: HE staining demonstrated that the intervention with HXMMT significantly improved the disordered cell arrangement, widened gaps, and thickened inner nuclear layer(INL)in ganglion cell layer GCL); retinal vascular diameter quantification revealed that the retinal vessel diameter of the MG significantly increased compared with the CG, and it was significantly changed after the intervention of HXMMT, with significant efficacy in the H-HX(P<0.05); transcriptomics profiling identified 1 470 reversed DEGs, predominantly enriched in the AMPK signaling pathway, FoxO signaling pathway, retinal developmental processes, and tight junction regulation. Technical validation confirmed strong correlation between qRT-PCR and RNA-seq data(R2=0.8571, P<0.05).CONCLUSION: HXMMT may improve retinal vascular microcirculation disorders in DR by regulating core targets including vsx1, pde6c, arr3a, plk1, fbp1b, foxo1a, pcna, and cdk1, as well as synergistically modulating processes such as retinal development in camera-type eyes, visual perception, microtubule cytoskeletal organization, tight junctions, and the AMPK signaling pathway, Foxo signaling pathway.

OBJECTIVE To identify core genes associated with the treatment of coronary heart disease （CHD） with Tongmai yangxin pills， and predict their potential immunological and metabolic mechanisms. METHODS Mendelian randomization （MR） analysis was conducted using protein quantitative trait loci （pQTL） data from the UK Biobank and Icelandic，and data from genome- wide association study to screen core genes related to Tongmai yangxin pills in the treatment of CHD. Gene expression changes were further validated using transcriptomic sequencing data. Mediation analyses of immune cells and plasma metabolites were subsequently performed to explore the downstream regulatory networks of these core genes. RESULTS A total of 62 positive pQTL genes showed significant causal associations with CHD. MR analysis combined with transcriptomic sequencing validation identified three core genes FAM3D，OXT， and ENPP5-associated with Tongmai yangxin pills in the treatment of CHD. The transcriptomic sequencing results showed that after treatment with Tongmai yangxin pills， the expression levels of FAM3D and OXT were significantly reduced （P＜0.01）， while the expression level of ENPP5 was significantly increased （P＜0.05）. Mediation analyses between immune cells and plasma metabolites indicated that these genes may positively or negatively regulate CHD through immune pathways involving regulatory T cells and myeloid dendritic cells expressing CD11c and CD62L， as well as through metabolic pathways related to lipid and fatty acid metabolism， cholesterol metabolism， and bile acid metabolism. CONCLUSIONS This study identified FAM3D，OXT， and ENPP5 as core genes associated with the treatment of CHD by Tongmai yangxin pills， which may exert therapeutic effects via modulation of immune cells and plasma metabolic pathways involving fatty acids and bile acids.

OBJECTIVE To investigate the changes of etiological submission rates before the antimicrobial therapy after a series of intervention measures were taken so as to optimize the use and management of antibiotics.METHODS A total of 97,146 patients who were hospitalized and treated with antibiotics in the First Affiliated Hospital of Soochow University from Jul.2021 to Jun.2024 were recruited as the research subjects.Jan.2023 was set as the time node of intervention,the time period from Jul.2021 to Dec.2022 was assigned as the pre-interven-tion group,and the time period from Jan.2023 to Jun.2024 was assigned as the post-intervention group.The etio-logical submission rates before the antimicrobial therapy were observed by interrupted time series before and after the intervention measures were taken.The changes of isolation rates of multidrug-resistant organisms and inci-dence of hospital-associated infections were estimated by chi-square test.RESULTS The etiological submission rates before the antimicrobial therapy,etiological submission rates before combined use of major antibiotics and etiological submission rates relating to diagnosis of hospital-associated infections were higher after the intervention than before the intervention(all P＜0.05).The interrupted time series analysis showed that from the perspective of long-term benefit,the intervention measures could raise the etiological submission rates before the use of re-stricted,special grades of antibiotics and general antibiotics,and the net benefits were 0.85％,0.67％and 0.68％,respectively(all P＜0.05);there was no significant difference in the etiological submission rate before the com-bined use of major antibiotics.After the intervention,the incidence of multidrug-resistant organisms infection de-creased from 0.46％to 0.27％(P＜0.001);the isolation rate of multidrug-resistant organisms was 25.73％after the intervention,27.47％before the intervention,and there was no significant difference.CONCLUSIONS Scientif-ic and reasonable interventions may effectively raise the etiological submission rates before the antimicrobial thera-py,however,the etiological submission rate for combined use of major antibiotics and the isolation rate of multi-drug-resistant organisms are not improved remarkably.It is necessary to further formulate targeted interven-tion measures so as to push forward high-quality development of infection control.

Objective:To develop a novel fibroblast activation protein (FAP) cyclic peptide imaging agent, Al 18F-FAP-NOX, evaluate its in vitro and in vivo properties, and explore its feasibility of PET/CT imaging in tumors with FAP positive expression. Methods:Al 18F-FAP-NOX was manually synthesized. The in vitro stability of Al 18F-FAP-NOX was determined using radio high performance liquid chromatography (HPLC). The lipid water partition coefficient log P, in vitro cell uptake experiments, microPET/CT imaging and biodistribution in 293T-FAP tumor-bearing mice were conducted to preliminarily evaluate the pharmacokinetics and biological efficacy of Al 18F-FAP-NOX. Afterwards, a patient (male, 65 years old) with lung cancer underwent Al 18F-FAP-NOX PET/CT imaging. Results:Al 18F-FAP-NOX was successfully synthesized with a yield of (26.28±2.31)% without attenuation correction ( n=4), and the radiochemical purity was more than 95%. Al 18F-FAP-NOX exhibited good stability and hydrophilicity (log P=-3.02±0.08, n=5). In cell assays, the uptake of Al 18F-FAP-NOX in HT1080-FAP cells reached the plateau phase at 15 min ((7.31±0.53) percentage activity of injection dose per million cells (%ID/mio cells)), exhibiting high cellular uptake. The uptake of Al 18F-FAP-NOX could be significantly inhibited by 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)-FAP-2286. The microPET/CT results of 293T-FAP tumor-bearing mice in vivo showed that Al 18F-FAP-NOX was highly uptaken in FAP-positive tumor tissues (60 min: (12.47±1.66) percentage activity of injection dose per gram of tissue (%ID/g)), while the uptake was very low in FAP-negative tumors. The biodistribution results were similar to the microPET/CT imaging results of tumor-bearing mice. The human clinical imaging showed an abnormal increase in Al 18F-FAP-NOX uptake (SUV max 5.5) of the lung cancer lesions. Conclusions:A novel cyclic peptide radiopharmaceutical, Al 18F-FAP-NOX, demonstrates good stability and hydrophilicity. It can be quickly distributed to tumor tissue in vivo. The human clinical PET/CT imaging shows certain diagnostic ability of Al 18F-FAP-NOX for lung cancer lesions. It is a promising cyclic peptide agent for PET imaging.

Objective:To systematically evaluate the safety and efficacy of the novel fibroblast activation protein (FAP)-targeted tracer 64Cu-FAP inhibitor (FAPI)-XT117 in patients with malignant solid tumors, and to compare with 18F-FDG. Methods:This self-controlled study was conducted on fifteen patients (8 males, 7 females; age (60 ±9) years) with malignant solid tumors from the First Affiliated Hospital of Guangzhou Medical University between July 2023 and December 2023. Each subject underwent 64Cu-FAPI-XT117 PET/CT at 30, 60, and 120min post-injection and was assigned to three dose cohorts (111MBq, 148MBq, and 185MBq; 5 patients in each cohort), and safety assessments were conducted within 24h after injection. In addition, all patients underwent 18F-FDG PET/CT at 60min post-injection. Time-activity curves were generated for 64Cu-FAPI-XT117, and the dosimetry was calculated. Image quality was evaluated using a 5-point Likert scale, and the optimal injected activity and imaging time point were determined. The paired t test was used to compare differences of the lesion detection count and SUV max between 64Cu-FAPI-XT117 and 18F-FDG PET/CT. Results:64Cu-FAPI-XT117 was well tolerated, with no adverse events reported. Time-activity curves of 68Ga-FAPI-XT117 revealed prominent uptake in the uterus, while the background activity in other organs remained low, with the whole-body effective dose of (0.0084±0.0021)mSv/MBq. The optimal imaging time point for 64Cu-FAPI-XT117 PET/CT was 60min post-injection, with an optimal administered activity of 111MBq. Compared with 18F-FDG, 64Cu-FAPI-XT117 demonstrated significantly higher uptake and more lesions in lymph-node metastases (SUV max: 8.6±3.8 vs 15.3±6.8, t=2.33, P=0.048; number of lesions: 8.3±5.4 vs 15.0±6.4; t=4.21, P=0.003) and distant metastases (SUV max: 11.8±3.7 vs 20.9±7.2, t=3.66, P=0.022; number of lesions: 7.0±3.2 vs 12.4±3.7, t=2.86, P=0.046). Conclusions:64Cu-FAPI-XT117 PET/CT is well tolerated in patients with solid tumors, with a controllable radiation risk. Moreover, it outperforms 18F-FDG PET/CT in the assessment of metastases.

Objective:To explore the effect of long noncoding RNA ANK3DT (lncRNA ANK3DT) on DNA damage repair ability and radiosensitivity of cervical cancer HeLa cells.Methods:The effect of lncRNA ANK3DT on the repair efficiency of DNA double-strand breaks (DSBs) was analyzed by the pre-constructed quantitative assay system based on the CRISPR/Cas9 system targeting homologous recombination (HR) and non-homologous end-joining (NHEJ) repair. Clone formation assay, flow cytometry, and immunofluorescence were used to detect the effects of down-regulation of lncRNA ANK3DT on cellular radiosensitivity, apoptosis and G 2/M phase arrest, and DSB repair after X-ray irradiation. Western blot, qPCR, and dual fluorokinase reporter gene plasmid was used to detect the effects of lncRNA ANK3DT on the HR repair-related protein CtIP expression and transcriptional regulation. Results:Down-regulation of lncRNA ANK3DT significantly inhibited HR repair and had no effect on NHEJ repair. The expression of lncRNA ANK3DT was significantly increased in HeLa cells at 24, 48, 72 h after X-ray irradiation ( t=-23.39, -88.83, -52.42, P<0.05). Down-regulation of lncRNA ANK3DT inhibited X-ray-induced DSB repair and increased apoptosis levels ( t=-14.63, P <0.05), prolonged G 2/M phase block ( t=-19.50, P <0.05), increased the radiosensitivity of HeLa cells (radiosensitization ratio=1.21), inhibited the CtIP promoter activity and decreased its mRNA and protein expression. Conclusions:lncRNA ANK3DT affects HR repair by regulating CtIP transcription, and down-regulation of lncRNA ANK3DT increases the radiosensitivity of HeLa cells by inhibiting DSB repair after ionizing radiation.